Plain-English translation of NCT07123727 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a safety and effectiveness study of Nogapendekin Alfa Inbakicept (also called ), a medication designed to boost your immune system. Researchers want to see if this treatment can help people who are still experiencing symptoms months after their COVID-19 infection has cleared. About 40 people with long COVID will participate.
Many people continue to suffer from symptoms like fatigue, brain fog, shortness of breath, and pain long after recovering from COVID-19 — sometimes for many months. Doctors don't yet have proven treatments for these lingering symptoms, so this study is testing whether stimulating the immune system in a new way might help people feel better.
You likely qualify if…
You likely don't qualify if…
You will receive doses of the study medication as part of this trial. While the exact details about visit schedules and duration aren't fully spelled out in this summary, you should expect to meet with the research team multiple times for check-ins, safety monitoring, and symptom assessments. The researchers will track how you feel and watch carefully for any side effects from the medication.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
ImmunityBio, Inc.
Enrollment target
~40 participants
Started
September 2025
Primary completion
July 2026
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kayleigh Russell
ImmunityBio, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.